Scarica l'app Stockscreener
3.03
0.98%
-0.03
Precedente Chiudi:
$3.06
Aprire:
$3.1
Volume 24 ore:
83,640
Relative Volume:
0.78
Capitalizzazione di mercato:
$33.89M
Reddito:
-
Utile/perdita netta:
$-19.25M
Rapporto P/E:
-1.7022
EPS:
-1.78
Flusso di cassa netto:
$-17.87M
1 W Prestazione:
-9.28%
1M Prestazione:
-16.30%
6M Prestazione:
-4.11%
1 anno Prestazione:
-5.02%
Intervallo 1D:
$2.9567
$3.15
Intervallo di 1 settimana:
$2.9567
$3.51
Portata 52W:
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
Nome
Lantern Pharma Inc
Settore
Industria
Telefono
972-277-1136
Indirizzo
1920 MCKINNEY AVENUE, DALLAS, TX
Confronta LTRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.03 | 34.22M | 0 | -19.25M | -17.87M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-07 | Iniziato | H.C. Wainwright | Buy |
Lantern Pharma Inc Borsa (LTRN) Ultime notizie
What analysts say about Lantern Pharma Inc stockMarket Capitalization Trends & Superior Capital Growth - earlytimes.in
Lantern Pharma Inc Stock Analysis and ForecastMACD Histogram Signals & Fast Profit Trading Strategies - earlytimes.in
Is Lantern Pharma Inc a good long term investmentResistance Breakout Alerts & Learn to Trade with Real-Time Feedback - earlytimes.in
Sentiment Recap: Is Lantern Pharma Inc. stock a safe buy before earningsWeekly Profit Summary & Free Expert Approved Momentum Trade Ideas - moha.gov.vn
What Wall Street predicts for Lantern Pharma Inc. stock priceJuly 2025 Update & Verified Entry Point Signals - Улправда
Lantern Pharma’s AI Bet Needs 2026 Trial Wins - Finimize
What momentum indicators show for Lantern Pharma Inc. stockEarnings Miss & AI Optimized Trade Strategies - DonanımHaber
Why Lantern Pharma Inc. stock remains resilientNew Guidance & Target Return Focused Stock Picks - Улправда
Lantern Pharma (NASDAQ:LTRN) Shares Down 6.4% – Should You Sell? - Defense World
Analyst Upgrade: Why Lantern Pharma Inc stock is rated strong buyTrade Entry Summary & Daily Chart Pattern Signals - moha.gov.vn
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Daily Commercial
Lantern Pharma announces LP-184 clinical trial met all primary endpoints - MSN
Lake Street Remains a Buy on Lantern Pharma (LTRN) - The Globe and Mail
Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors - Digital Journal
Will Lantern Pharma Inc. stock benefit from automationTreasury Yields & AI Forecasted Stock Moves - Newser
Will Lantern Pharma Inc. stock rally after Fed decisionsPortfolio Return Report & Low Volatility Stock Suggestions - Newser
Lantern Pharma advances AI-Driven cancer drug after successful Phase 1a trial - Proactive financial news
Lantern’s cancer drug LP-184 shows promise in phase 1a trial - Investing.com Australia
Lantern Pharma (LTRN) Advances with Promising Clinical Insights from Phase 1a Study - GuruFocus
Lantern Pharma reports additional positive LP-184 Phase 1a results showing durable disease control in heavily pre-treated advanced cancer patients - marketscreener.com
Lantern’s cancer drug LP-184 shows promise in phase 1a trial By Investing.com - Investing.com South Africa
Lantern Pharma Reports Positive Phase 1a Data For LP-184 In Advanced Solid Tumors - Nasdaq
Lantern Pharma Inc. (LTRN) Rises 9.5% in Pre-market: Amid Routine Trading - Stocks Telegraph
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials - Yahoo Finance
Can Jai Balaji Industries Limited Sustain EPS Growth Under Competitive PressureMorning Star Patterns & Zero-Cost Stock Research by Professionals - earlytimes.in
BIOS Capital Management LP Sells 131,757 Shares of Lantern Pharma Inc. $LTRN - Defense World
Is Lantern Pharma Inc. stock vulnerable to regulatory risksTrade Volume Report & Real-Time Chart Breakout Alerts - newser.com
Is Lantern Pharma Inc. stock oversold or undervaluedJuly 2025 News Drivers & Entry and Exit Point Strategies - newser.com
How Lantern Pharma Inc. stock reacts to global recession fearsMarket Activity Report & Reliable Volume Spike Alerts - newser.com
Here's Why Lantern Pharma (NASDAQ:LTRN) Must Use Its Cash Wisely - Sahm
Can Lantern Pharma Inc. stock deliver consistent earnings growth2025 EndofYear Setup & Proven Capital Preservation Methods - newser.com
Is Lantern Pharma Inc. stock a buy before product launchesTrade Entry Summary & Daily Growth Stock Investment Tips - newser.com
Lantern Pharma Inc Azioni (LTRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lantern Pharma Inc Azioni (LTRN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
| Fletcher Aaron G.L. | 10% Owner |
May 29 '25 |
Sale |
3.03 |
20,200 |
61,206 |
54,792 |
| Fletcher Aaron G.L. | 10% Owner |
May 28 '25 |
Sale |
2.87 |
15,000 |
43,050 |
55,753 |
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):